Amyloidosis refers to a group of diseases caused by deposits of abnormal proteins, known as amyloid, in one or more organs of the body. Deposition of amyloid in the heart is known as cardiac amyloidosis or amyloid heart disease.
The Cardiac Amyloidosis Program at Brigham and Women’s Hospital (BWH) is the only program in the country devoted exclusively to cardiac amyloidosis. Our program—featuring a multidisciplinary team of experts—specializes in the diagnosis and treatment of this rare and often misdiagnosed condition. We are committed to educating patients and physicians and spreading awareness.
Led by Rodney H. Falk, MD, widely recognized as a cardiac amyloidosis expert, our team includes specialists in cardiology, cardiac pathology, gastroenterology, hematology, nephrology, neurology and cardiac research – all Harvard Medical School faculty with extensive experience in cardiac amyloidosis. We work closely with patients and referring physicians, providing the highest standard of medical and supportive care, combined with cutting-edge research and clinical trials. An international referral site, the Cardiac Amyloidosis program is part of the Brigham and Women’s Hospital Heart & Vascular Center and is located within the state-of-the-art Shapiro Cardiovascular Center.
Call: Dr. Falk at (617) 525-7053
Fax: (617) 264-5265
Hours: 8AM-4PM, Monday-Friday
Referring physicians can refer a patient online or call (857) 307-4000 to learn how to refer a patient to the Cardiac Amyloidosis Program.
The Cardiac Amyloidosis Program is conducting research into a variety of aspects of amyloidosis:
For over a century, a leader in patient care, medical education and research, with expertise in virtually every specialty of medicine and surgery.